Skip to content

The Policy Vault

Methodology Why Contact

Coverage / Medica / Nexavar (sorafenib) / Myeloid/lymphoid neoplasms with eosinophilia (FLT3 rearrangement)

Nexavar (sorafenib) — Medica

Myeloid/lymphoid neoplasms with eosinophilia (FLT3 rearrangement)

Initial criteria

age ≥ 18 years
tumor has FLT3 rearrangement

Approval duration

1 year

Provenance

View official policy PDF

Plan: Medica
Drug: Nexavar (sorafenib)
Indication: Myeloid/lymphoid neoplasms with eosinophilia (FLT3 rearrangement)
Last seen: 2025-10-06
Hash: 2ff8eb75ec61…

Disclaimer: Educational only. Coverage varies by employer group and formulary. Always verify with the plan.

Consult

Curious about trends across plans?

I can walk you through how this policy compares and share data-backed patterns. Short call, straight answers.

Email to start a quick consult What I cover (overview)

No commitments—just a brief conversation to see if it’s helpful.

The Policy Vault

Structured prior authorization and step-therapy criteria for commercial health plans. Built by pharmacists for healthcare professionals.

Disclaimer: Educational use only. Coverage varies by employer group and formulary. Always verify with the plan.

Product

Coverage Directory
Why Policy Vault
Methodology

Company

Contact
Press
Support

© 2025 The Policy Vault. Data sourced from official health plan documents.